Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035950 | 1.00 | IDO1 (0.53) | IDO1TDO2ALDH1A1TSHRKDM4E | |
| SCHEMBL3712217 | 0.96 | ALDH1A1 (0.58) | IDO1TDO2ALDH1A1TSHRKDM4E | |
| SCHEMBL3712215 | 0.96 | ALDH1A1 (0.58) | IDO1TDO2ALDH1A1TSHRKDM4E | |
| SCHEMBL1819133 | 0.85 | IDO1 (0.53) | IDO1TDO2ALDH1A1KDM4ECD274 | |
| SCHEMBL2027597 | 0.85 | IDO1 (0.53) | IDO1TDO2ALDH1A1KDM4ECD274 | |
| SCHEMBL9154842 | 0.85 | IDO1 (0.53) | IDO1TDO2ALDH1A1KDM4ECD274 | |
| SCHEMBL2032294 | 0.84 | CYP1A2 (0.51) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL1817183 | 0.84 | CYP1A2 (0.51) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL3148407 | 0.84 | CYP1A2 (0.51) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL2029008 | 0.83 | MAOA (0.60) | IDO1TDO2ALDH1A1KDM4ECD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747882-A1 | DATA STORAGE USING PROTEINS | The Hong Kong Polytechnic University (CN) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025015598-A1 | DATA STORAGE USING PROTEINS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2025-01-23 | — | — | WO | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | disclosed |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | Karoyan, Philippe (FR) | 2023-09-19 | — | — | US | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11302421-B2 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-04-12 | — | — | US | disclosed |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2022-03-24 | — | — | US | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1863832-A1 | AGE INHIBITORS | Pharmamens (FR) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2006103274-A9 | AGE INHIBITORS | PHARMAMENS (FR) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006103274-A1 | AGE INHIBITORS | PHARMAMENS (FR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | IDO1 3425/4885TDO2 1770/4885ALDH1A1 749/4885 |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | VIP, RNASE1, ABCB11 | IDO1 771/4885TDO2 4423/4885ALDH1A1 1766/4885 |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | IDO1 771/4885TDO2 4423/4885ALDH1A1 1766/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | IDO1 3207/4885TDO2 1045/4885ALDH1A1 323/4885 |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | IDO1 3425/4885TDO2 1770/4885ALDH1A1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.